Drug patent portfolios are often treated like static assets—filed, granted, and then quietly shelved. But in today’s litigation-aware landscape, that mindset is increasingly expensive. The real competitive edge comes from designing your patent strategy…

Hospitals are sitting on a quiet competitive advantage—and many are ignoring it.
In the pharmaceutical supply chain, the most valuable “weapon” isn’t a new drug launch. It’s timing. Specifically: patent expiration intelligence.
A recent DrugPatentWatch…

Most teams don’t “miss” generic launches—they miss the timing.
In generic drug forecasting, being wrong by a few months can be the difference between capturing share and watching competitors lock in contracts, inventory, and payer conversations first…

Pharma’s “hidden talent” isn’t in the lab—it’s in the Orange Book.
Most people think the FDA Orange Book is just a regulatory filing: a list of approved drugs, patents, and exclusivities. But if you’re trying to find who is actually building defensib…

Biotech investors love a good story. But portfolio winners are usually built on something less glamorous: how you rank risk, timing, and value across a pipeline.
That’s where two metrics—Net Present Value (NPV) and the Profitability Index (PI)—move fro…

Biopharma is entering a talent cliff—one that looks less like a spreadsheet problem and more like a competitive intelligence problem.
Here’s the hook: while everyone is focused on the “patent cliff,” recruiters are quietly preparing for a different cli…

Stop Overstocking. Patent Intelligence Is the New Risk Control for Wholesalers.
Overstocking branded drugs isn’t just a balance-sheet problem—it’s a timing problem.
For wholesalers, the risk is rarely about demand collapsing overnight. It’s about what …

Big Pharma doesn’t just “restructure” when a patent cliff hits. It signals.
If you want to understand workforce shifts before they show up in earnings calls, look past the press releases and into the patent cliff events themselves. The hidden hiring si…

Biosimilar sourcing is no longer a procurement exercise—it’s an IP strategy.
If you’re planning a switch from an originator biologic to a biosimilar, the hardest part isn’t finding a supplier. It’s timing the switch so you don’t get blindsided by exc…

Pharma has a familiar playbook: take an old molecule, repackage the story, and charge like it’s new.
That’s the tension at the heart of “old drugs, new prices”—a strategy increasingly used for repurposed medicines, where companies argue that premium pr…